In the UK, a consortium of public and private companies have been awarded part of a £53 million ($73 million) grant from UK Research and Innovation (UKRI) and the Made Smarter initiative.
Industry partners Catalent (NYSE: CTLT), Siemens, GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) are among the companies which will work together to introduce a proof of concept approach to a new digital supply chain.
The Digital Medicines Manufacturing Research Centre will be based at Strathclyde, Cambridge and Loughborough Universities, and will aim to create digital supply chains enabling clinical trials to operate more flexibly.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze